Hengrui's HRS-4139 Wins NMPA Clinical Trial Approval – Class 1 First‑in‑Target Candidate Targets Moderate‑to‑Severe Plaque Psoriasis
CompanyDrug

Hengrui’s HRS-4139 Wins NMPA Clinical Trial Approval – Class 1 First‑in‑Target Candidate Targets Moderate‑to‑Severe Plaque Psoriasis

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its drug HRS‑4139 has been approved by China's National Medical Products Administration (NMPA) for clinical trials targeting moderate‑to‑severe plaque…

IASO Bio's In Vivo CAR‑T IASO208 Receives FDA Implicit IND Approval – Off‑the‑Shelf CD20 Therapy Targets Relapsed/Refractory B‑NHL
CompanyDrug

IASO Bio’s In Vivo CAR‑T IASO208 Receives FDA Implicit IND Approval – Off‑the‑Shelf CD20 Therapy Targets Relapsed/Refractory B‑NHL

Chia Tai Tianqing's Dual Category 1 Biologics Applications Accepted by NMPA – TQB2102 HER2‑Low ADC and TQH2722 IL‑4Rα Antibody Advance Toward Approval
CompanyDrug

Chia Tai Tianqing’s Dual Category 1 Biologics Applications Accepted by NMPA – TQB2102 HER2‑Low ADC and TQH2722 IL‑4Rα Antibody Advance Toward Approval

CSPC's SYS6010 Granted NMPA Breakthrough Therapy Designation – EGFR‑Targeting ADC for Refractory Non‑Squamous NSCLC
CompanyDrug

CSPC’s SYS6010 Granted NMPA Breakthrough Therapy Designation – EGFR‑Targeting ADC for Refractory Non‑Squamous NSCLC

Gilead and PAHO Sign Agreement to Expand Twice-Yearly Lenacapavir PrEP Access Across Latin America and the Caribbean
CompanyDeals

Gilead and PAHO Sign Agreement to Expand Twice-Yearly Lenacapavir PrEP Access Across Latin America and the Caribbean

- Advertisement -
Ad image
CompanyDeals

Johnson & Johnson Invests $1 Billion in Jacksonville Vision Facility – Expands ACUVUE Manufacturing and Distribution

Lynk Pharmaceuticals Files for Hong Kong IPO – Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders
CompanyDeals

Lynk Pharmaceuticals Files for Hong Kong IPO – Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders

Bayer Secures FDA Approval for Ambelvist – Novel High-Relaxivity MRI Contrast Agent with Lower Gadolinium Dose
Others

Bayer Secures FDA Approval for Ambelvist – Novel High-Relaxivity MRI Contrast Agent with Lower Gadolinium Dose

Shanghai Leadingtac Secures NMPA Approval for LT-010391 – China's First Clinical-Stage Oral KRAS-G12D Degrader
CompanyDrug

Shanghai Leadingtac Secures NMPA Approval for LT-010391 – China’s First Clinical-Stage Oral KRAS-G12D Degrader

CompanyDrug

Fosun Pharma Secures NMPA Approval for Fumaining in Pediatric Langerhans Cell Histiocytosis – Expands MEK Inhibitor Franchise

TriApex Laboratories Files for Hong Kong IPO – Next-Generation CRO with 240+ NMPA Approvals
CompanyDeals

TriApex Laboratories Files for Hong Kong IPO – Next-Generation CRO with 240+ NMPA Approvals

Ningbo Sanxing Medical Electric Files HKEX Prospectus with Dual Business Model in Power Equipment and Rehabilitation Services
CompanyDeals

Ningbo Sanxing Medical Electric Files HKEX Prospectus with Dual Business Model in Power Equipment and Rehabilitation Services

CompanyDrug

Gritpharma Secures NMPA Approval for Doxylamine as China’s First Novel Short-Term Insomnia Treatment

Baheal Pharma Partners with Jinan Junxin Hospital to Launch ZAP-X Precision Radiosurgery Center
CompanyDeals

Baheal Pharma Partners with Jinan Junxin Hospital to Launch ZAP-X Precision Radiosurgery Center

Lannacheng Biotechnology Files HKEX Prospectus with 13-Candidate Radiopharmaceutical Pipeline
CompanyDeals

Lannacheng Biotechnology Files HKEX Prospectus with 13-Candidate Radiopharmaceutical Pipeline

CompanyLegal / IP

Harbour BioMed Wins $20.2 Million Patent Verdict Against Amgen in Delaware Court

CompanyDrug

Sichuan Biokin’s Iza-Bren Becomes World’s First EGFR×HER3 Bispecific ADC with NDA Accepted by China’s NMPA

Show More